Abstract: Objective To evaluate the drug use and its rationality among patients with acute ST segment elevation myocardial infarction treated with clinical pathways (CP). Methods The clinical data on STEMI patients who had implemented CP in our hospital between January 1, 2018 and December 31, 2019 was collected. The drug utilization index (DUI), evaluation index, diagnosis, effect of therapeutic drug monitoring and that of clinical diagnosis and treatment were analyzed using methods for drug use review and drug use evaluation. Results There were thirty-eight main types of drugs used by seventy-six patients. The DUI for five of these types was above 1, less than 1 for twenty types, and was 1 for thirteen types. Aspirin enteric coated tablets, clopidogrel bisulfate tablets, atorvastatin calcium tablets, ticagrelor tablets, pantoprazole enteric coated tablets, isosorbide mononitrate tablets and trimetazidine hydrochloride tablets were high in drug use intensity. All 76 patients were monitored for the first time after admission for myocardial injury, liver function, renal function, blood routine examination and blood lipid level; During the treatment, 100.00%, 40.78%, 22.36%, 9.21% and 3.94% of them received the monitoring of myocardial injury markers, liver function, renal function, blood routine and blood lipid levels and abnormal re monitoring respectively. There were nine cases of adverse drug reaction ADR. After treatment, the clinical symptoms of the seventy-six cases (100.00%) improved significantly. Conclusion The combination of DUR and DUE can comprehensively evaluate the drug use of STEMI patients treated with CP. Irrational drug use should be detected in time and rational use of clinical drugs promoted.

Key words: ST elevated myocardial infarction, clinical pathway, drug utilization review, drug utilization evaluation, drug utilization index, adverse drug reaction